COPD: a slope you can bend but not rewind

Start here: what COPD is

Breathing out is supposed to be passive. The lung is elastic; it recoils, and air leaves. Chronic obstructive pulmonary disease (COPD) is what happens when that stops working — persistent airflow obstruction that does not fully reverse, so emptying the lungs becomes slow and effortful and air gets trapped behind.

Two processes produce it, usually together. Emphysema is destruction of the alveolar walls: the lung loses the elastic recoil that drives expiration, and loses gas-exchange surface at the same time. Chronic bronchitis and small-airway disease is inflammation, mucus and remodelling in the conducting airways, narrowing them from the inside. The small airways are where most of the resistance accumulates, and small-airway pathology is now understood as central rather than incidental ^{[1] [2]}.

What causes it. Overwhelmingly tobacco smoke — a meta-analysis of the epidemiological evidence quantifies the relation of smoking to COPD, chronic bronchitis and emphysema ^[3]. But not only. In the population-based Burden of Obstructive Lung Disease study across 14 countries, never-smokers made up 23.3% of everyone classified with GOLD stage II+ COPD ^[4]. Household air pollution from biomass and coal fuels is a major driver where those fuels are burned indoors ^{[5] [6]}, and occupational dust exposure contributes — which is where this review meets its siblings, below.

Scale. COPD is one of the largest causes of death worldwide, and was projected two decades ago to rise into the top ranks of global mortality as populations aged and smoking exposure accumulated ^{[7] [8]}. It is also systematically under-recognized: the diagnosis requires a breathing test that many at-risk people never receive, and reduced FEV₁ has been argued to be "not just a lung function test but a marker of premature death from all causes," identifying undiagnosed COPD and flagging risk of lung cancer, coronary disease and stroke as well ^[9].

Why it is in the news. For decades COPD had no targeted biologic therapy of the kind that transformed severe asthma. That changed with dupilumab, tested in two phase 3 trials in patients with COPD and blood-eosinophil evidence of type 2 inflammation ^{[10] [11]} — the first biologic to work in this disease, and the subject of the Progress section.

How it relates to the occupational lung diseases in this series. COPD is the obstructive disease; black lung and silicosis are classically restrictive and nodular — scar tissue and fibrotic nodules that make the lung small and stiff rather than slow to empty. But the boundary leaks in both directions. Occupational silica exposure independently causes COPD — and does so "even in the absence of radiological signs of silicosis," with the association between cumulative silica dust exposure and airflow obstruction independent of silicosis itself ^[12]. Occupational exposure to vapours, gases, dusts and fumes accounts for a population attributable fraction of 14% of COPD, and occupational COPD remains substantially underdiagnosed ^{[13] [14] [15]}. Dust-exposed workers carry both diseases at once often enough that the combination has been studied as its own entity ^[16], construction workers exposed to inorganic dust show increased COPD mortality ^[17], and never-smokers' COPD prevalence has been mapped by industry and occupation ^[18]. Reading the three together is the point: same organ, same dusts, different mechanical failure.

Three pillars follow — measurements, medicines, and progress — with the field's most famous figure in between.

Pillar 1: measurements and diagnosis

Spirometry, and the number that defines the disease

COPD is defined by a test, not by symptoms or an image. A person blows out as hard and fast as they can into a spirometer, which records two numbers: FVC, the total volume exhaled, and FEV₁, the volume exhaled in the first second. The ratio FEV₁/FVC is the fraction of the lung emptied in one second, and it is the diagnostic quantity.

GOLD requires spirometry for the clinical diagnosis of COPD "to avoid misdiagnosis and to ensure proper evaluation of severity of airflow limitation," and the threshold is a post-bronchodilator FEV₁/FVC below 0.70 — post-bronchodilator because the obstruction must be shown to persist after a reliever inhaler, which is what distinguishes it from asthma ^{[19] [4]}. Interpretation of the numbers against reference equations follows standard strategies ^{[20] [21]}.

Once obstruction is established, FEV₁ as a percent of predicted grades its severity, and GOLD's assessment then adds two more axes: symptom burden and exacerbation history, splitting patients into categories rather than ranking them on airflow alone. As GOLD puts it, assessment "should always include assessment of (1) symptoms, (2) severity of airflow limitation, (3) history of exacerbations, and (4) comorbidities" ^[19]. That matters because the same FEV₁ can belong to a person who is barely troubled and a person hospitalized three times a year, and they need different treatment.

Obstructive versus restrictive — the contrast with the dust diseases

This is the cleanest way to see what "obstructive" means. In COPD, FEV₁ falls further than FVC, so the ratio drops below 0.70: the lung may hold plenty of air, it just cannot get it out quickly. In classic silicosis and coal workers' pneumoconiosis, fibrosis makes the lung stiff and small, so FEV₁ and FVC fall together and the ratio is preserved or even high — a restrictive pattern ^[20]. In practice the dust diseases often produce mixed patterns, because the same exposures also inflame airways ^{[12] [16]} — which is precisely why the black-lung and silicosis reviews both discuss spirometry rather than imaging alone.

What the ratio misses

Two findings complicate the clean threshold, and both are active problems.

Smokers with normal spirometry are not necessarily well. In the COPDGene cohort, a group with FEV₁/FVC above 0.7 and FEV₁ at least 80% predicted — formerly dismissed as "GOLD 0" — showed measurable respiratory symptoms, physical-function impairment and CT abnormalities ^[22]. Preserved ratio impaired spirometry (PRISm) — a normal ratio with a reduced FEV₁ — is a distinct and common phenotype with its own epidemiology and genetics ^[23].

Imaging adds what spirometry cannot see. Quantitative CT separates emphysema, air trapping and airway-wall thickening as distinct contributors to the same measured obstruction ^[24].

Alpha-1 antitrypsin: the one genetic cause to test for

Most COPD is acquired, but a minority is inherited. Alpha-1 antitrypsin is a circulating protease inhibitor whose job is to restrain neutrophil elastase in the lung; its severe deficiency leaves that enzyme free to digest alveolar walls, causing early emphysema and, separately, liver disease ^{[25] [26]}. The clinical importance of testing is that it changes management and family screening; ATS/ERS standards and a later ERS statement set out diagnosis and treatment ^{[27] [28]}. Smoking and deficiency compound each other brutally — decline in FEV₁ has been analysed specifically by smoking status in PiZZ individuals ^[29].

Centerpiece: a simple simulatable model of decline

Everything above is a snapshot. What determines a patient's future is the rate at which FEV₁ falls, and the field's defining picture is a plot of exactly that.

Model FEV₁ as declining linearly with age from the start of adult life:

FEV₁(a) = FEV₁(a₀) − s · (a − a₀)

where s is the annual rate of decline. The construct has two slopes: a normal rate that everyone experiences with ageing, and an accelerated rate in susceptible smokers. Quitting is modelled as a change of slope at the quit age:

s(a) = s_smoker for a ≤ a_quit, and s_normal for a > a_quit

Grounding. This normal-versus-accelerated-decline construct is the object the FEV₁-decline literature is explicitly built around — a review of decline by age and smoking status frames it as needing "a concept of what constitutes both a normal level and a normal decline and, consequently, an unusually low level and accelerated decline" ^[30]. The slope change on quitting is not an assumption either: the Lung Health Study randomized 5,887 smokers aged 35–60 with spirometric signs of early COPD to smoking intervention with or without an inhaled anticholinergic, or to no intervention, and measured the rate of change of FEV₁ over five years — participants in the two smoking-intervention groups "showed significantly smaller declines in FEV₁ than did those in the control group" ^{[31] [32]}. And measured decline rates in established COPD sit squarely in the tens of mL/year: frequent exacerbators declined at −40.1 mL/year against −32.1 mL/year in infrequent exacerbators ^[33].

Parameters are illustrative and flagged. The specific slopes used below (30 mL/year normal, 65 mL/year for a susceptible smoker), the 4.0 L starting value, and the 1.0 L impairment threshold are teaching values chosen to make the geometry legible — not estimates for any individual. What the figure asserts structurally is the part that matters, and the script enforces it: at the quit age the quitter's FEV₁ equals the continuing smoker's exactly, with no upward jump.

What the model explains. Three things, and the third is the reason the figure is famous.

First, why COPD appears suddenly in a person who has been losing function for thirty years. The decline is silent until FEV₁ approaches the level where breathlessness begins. Nothing changes about the slope at diagnosis; only the patient's awareness changes.

Second, why the disease is a slope problem, not a level problem. Two people with the same FEV₁ today have entirely different futures depending on their rate of decline, which is why exacerbation frequency matters so much — it is associated with faster decline ^[33].

Third — the teaching point — quitting bends the slope but does not rewind it. The quitter's curve leaves the smoker's line at the quit age and continues downward at the normal rate; the FEV₁ already lost stays lost. The benefit is therefore proportional to the years remaining after quitting: 1,225 mL at age 80 for quitting at 45, but only 525 mL for quitting at 65. This is the argument for early cessation stated as arithmetic, and it echoes the observation that cessation before roughly age 45–50 may keep FEV₁ within normal values ^[9].

Limits, honestly. Real trajectories are not straight lines, and the literature is explicit about the "fallacies" in over-reading this picture ^[30]. Lung function does not simply decline from a common peak — people arrive at adulthood with different maximally attained FEV₁, and a low peak is its own route into COPD. Decline is not uniform: it varies with exacerbations ^[33], with body mass ^[34], and between individuals in ways cohort studies have struggled to predict. And the original picture's neat separation into "susceptible" and "non-susceptible" smokers is a simplification of a continuous distribution of risk.

Pillar 2: medicines and management

The honest frame first: the airflow obstruction is largely irreversible. No available therapy restores destroyed alveoli or reverses airway remodelling. So management has exactly two goals — slow the decline and prevent exacerbations — plus symptom relief and functional support.

The one intervention that changes the slope

Smoking cessation. It is the only intervention shown to alter the rate of FEV₁ decline, which the Lung Health Study established in a randomized design ^{[31] [32]}, and its effect on symptoms, lung function, airway hyperresponsiveness and inflammation has been characterized directly ^{[35] [36]}. Cessation in people who already have respiratory disease is treated as an integral component of therapy rather than general advice ^{[37] [38]}, supported by behavioural and pharmacological aids ^[39], and even simple feedback framings such as telling smokers their "lung age" have been tested in randomized trials to improve quit rates ^[40].

Everything that follows treats symptoms and events. Only this changes the trajectory.

Bronchodilators: the backbone

Two receptor systems relax airway smooth muscle, and both are targeted with long-acting inhaled drugs.

• LAMAs (long-acting muscarinic antagonists) block acetylcholine at the M3 muscarinic receptor, removing resting cholinergic bronchoconstrictor tone. Tiotropium is the archetype; a four-year trial and long-term evaluations established sustained benefit in symptoms and health outcomes ^{[41] [42] [43]}.
• LABAs (long-acting β₂-agonists) stimulate the β₂-adrenergic receptor, relaxing smooth muscle through cyclic AMP.
• LAMA/LABA combinations act on both pathways at once; dual bronchodilation outperformed single bronchodilator therapy ^[44], and in FLAME the LAMA/LABA combination indacaterol–glycopyrronium was compared head-to-head against a LABA/ICS combination for exacerbation prevention ^[45].

Bronchodilators make breathing easier and reduce exacerbations. Notably, the anticholinergic arm of the Lung Health Study did not change the rate of FEV₁ decline ^[31] — the slope and the symptoms are different targets.

Inhaled corticosteroids: for the right patients

ICS were once given broadly and are now targeted, because the benefit is concentrated and the harms are real. Early trials of fluticasone in moderate-to-severe COPD and of combination LABA/ICS established effects on exacerbations and health status ^{[46] [47] [48]}, and TORCH tested salmeterol–fluticasone against survival ^{[49] [50]}.

The refinement came from a biomarker. Blood eosinophil count predicts who responds: eosinophil counts were associated with exacerbation reduction from adding inhaled fluticasone furoate to vilanterol ^[51], and in the WISDOM withdrawal study eosinophil count predicted which patients deteriorated when ICS were removed ^{[52] [53]}. Eosinophilic inflammation is present in a substantial minority of COPD ^{[54] [55]} and is now framed as a treatable trait rather than a curiosity ^[56].

Exacerbations: the events that drive the disease

An exacerbation is an acute worsening beyond normal day-to-day variation, and defining them precisely has been its own literature ^{[57] [58] [59]}. They matter for three reasons the substrate quantifies. They are frequent and phenotypic — in ECLIPSE, exacerbation rates rose with GOLD stage (0.85, 1.34 and 2.00 per person-year for stages 2, 3 and 4), and a frequent-exacerbator phenotype existed independently of severity ^[60]. They accelerate decline ^[33]. And they kill: in a prospective cohort of 304 men followed five years, patients with three or more severe exacerbations had a hazard ratio for death of 4.13 ^[61].

Acute treatment uses systemic glucocorticoids ^[62], and non-invasive ventilation for acute hypercapnic exacerbations is one of the strongest interventions in respiratory medicine ^[63].

Non-drug management, which is not optional

Pulmonary rehabilitation — supervised exercise plus education — improves health-related quality of life and exercise capacity, established by Cochrane review and endorsed in official statements ^{[64] [65] [66] [67]}; delivered after an exacerbation it has its own evidence base ^[68], and its effects register on integrated indices such as BODE ^[69]. Long-term oxygen therapy improves survival in appropriately hypoxaemic patients, with trials delineating where the benefit stops in moderate hypoxaemia ^[70]. For selected severe emphysema, lung-volume-reduction surgery was compared against medical therapy in a randomized trial ^[71].

Alpha-1 antitrypsin augmentation

For the deficient minority, intravenous augmentation replaces the missing protease inhibitor. Whether it slows FEV₁ decline has been examined directly ^{[72] [73]}, and CT lung densitometry proved a more sensitive endpoint than spirometry for detecting the effect on emphysema progression ^[74], within the framework set by ATS/ERS and ERS statements ^{[27] [28]}.

Pillar 3: progress

The first biologic. Dupilumab is a monoclonal antibody blocking the shared receptor component for interleukin-4 and interleukin-13, the central drivers of type 2 inflammation. Two phase 3, double-blind, randomized trials enrolled patients with COPD, a blood eosinophil count of at least 300 cells per microlitre, and elevated exacerbation risk despite standard triple therapy; the primary endpoint in both was the annualized rate of moderate or severe exacerbations, with prebronchodilator FEV₁ and St George's Respiratory Questionnaire score as key secondary endpoints. BOREAS randomized 939 patients ^[10] and NOTUS confirmed the finding in a second trial of 935 ^[11]. The significance is not only the effect size but the precedent: a biomarker-selected subgroup of COPD turned out to be treatable with a targeted antibody, after a long run of biologics that worked in asthma and failed here ^{[75] [76]}.

Eosinophil-guided therapy more broadly. The same biomarker now runs through ICS decisions ^{[51] [52]} and biologic selection, and the conceptual shift is from treating "COPD" to treating identified traits within it ^{[56] [54]}.

Finding the disease earlier. The COPDGene and PRISm work shows substantial disease below the diagnostic threshold ^{[22] [23]}, and FEV₁ is argued to deserve use as a general risk marker in smokers rather than a confirmatory test after symptoms appear ^[9]. If the model above is right that the slope is what matters, then finding people while they still have FEV₁ to protect is where the leverage is.

Mechanism. Oxidative stress and redox dysregulation of lung inflammation remain the core of the pathogenic account ^{[1] [77]}, with Nrf2 identified as a protective pathway whose loss worsens smoke-induced emphysema in mice ^{[78] [79] [80]}. COPD is also increasingly framed as a systemic disease: persistent systemic inflammation defines a phenotype with poorer outcomes ^{[81] [2]}.

And the parts that are not medicine. Roughly a quarter of GOLD stage II+ COPD occurs in never-smokers ^[4], and household biomass smoke is a leading cause in much of the world ^{[5] [6]}. Reducing that exposure is a housing and energy problem, not a pharmacological one — the same structural point the silicosis and black lung reviews make about dust control.